The immunohistochemical evaluation showed that EpCAM and CEA could be suitable targets for response evaluation after NAT, since the expression of these targets in the primary tumor bed was low compared with the diagnostic biopsy and adjacent pre-existent rectal mucosa in more than 90% of patients with a pCR [106]. The gene discussed is CEACAM5; the disease is neoplasm.